Monitoring of Donor‐Derived Cell‐Free DNA by Short Tandem Repeats: Concentration of Total Cell‐Free DNA and Fragment Size for Acute Rejection Risk Assessment in Liver Transplantation

Esther Fernández‐Galán, Celia Badenas, Constantino Fondevila, Wladimiro Jiménez, Miquel Navasa, Joan Anton Puig‐Butillé, Mercè Brunet – 17 August 2021 – Monitoring of graft function is essential during the first months after liver transplantation (LT), but current liver function tests (LFTs) lack the specificity and sensitivity to ensure an efficient diagnosis of acute rejection (AR). Recently, donor‐derived cell‐free DNA (ddcfDNA) has emerged as a noninvasive biomarker to assess graft integrity.

Graft Survival and Segment Discards Among Split‐Liver and Reduced‐Size Transplantations in the United States From 2008 to 2018

John R. Montgomery, Alexandra Highet, Craig S. Brown, Seth A. Waits, Michael J. Englesbe, Christopher J. Sonnenday – 17 August 2021 – Split‐liver transplantation has allocation advantages over reduced‐size transplantation because of its ability to benefit 2 recipients.

Novel Composite Endpoint for Assessing Outcomes in Liver Transplantation: Arterial and Biliary Complication–Free Survival

Eric Savier, Yann De Rycke, Chetana Lim, Claire Goumard, Geraldine Rousseau, Fabiano Perdigao, Pierre Rufat, Chady Salloum, Laura Llado, Emilio Ramos, Josefina Lopez‐Dominguez, Alba Cachero, Joan Fabregat, Daniel Azoulay, Olivier Scatton – 16 August 2021 – Transplant and patient survival are the validated endpoints to assess the success of liver transplantation (LT). This study evaluates arterial and biliary complication–free survival (ABCFS) as a new metric.

More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC

Alberto Zanetto, Elena Campello, Cristiana Bulato, Sabrina Gavasso, Graziella Saggiorato, Sarah Shalaby, Luca Spiezia, Umberto Cillo, Fabio Farinati, Francesco Paolo Russo, Patrizia Burra, Marco Senzolo, Paolo Simioni – 15 August 2021 – In patients with cirrhosis, particularly those with hepatocellular carcinoma (HCC), hypercoagulability may be associated with purported increased risks of portal vein thrombosis and cirrhosis progression.

Subscribe to